Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAM Combination Therapy for Newly Diagnosed Multiple Myeloma
NCT00317811Phase 2Completed
- Sponsor
- ONCOtherapeutics
- Start
- Nov 2005
- Primary completion
- Feb 2009
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by ONCOtherapeutics. Started Nov 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00317811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00317811.